Multiple drug resistant mechanisms against darunavir, amprenavir, and nelfinavir of HIV-1 PR

被引:2
|
作者
Liu, Xiaoqing [1 ]
Dai, Qi [2 ]
Xiu, Zhilong [3 ]
机构
[1] Hangzhou Dianzi Univ, Sch Sci, Hangzhou 310018, Peoples R China
[2] Zhejiang Sci Tech Univ, Coll Life Sci, Hangzhou 310018, Peoples R China
[3] Dalian Univ Technol, Dept Biosci & Biotechnol, Sch Environm & Biol Sci & Technol, Dalian 116024, Peoples R China
基金
中国国家自然科学基金;
关键词
HIV-1; PR; Inhibitor; Resistance; Mutation; Molecular dynamics simulation; HUMAN-IMMUNODEFICIENCY-VIRUS; ORALLY BIOAVAILABLE INHIBITOR; MOLECULAR DYNAMIC SIMULATIONS; PROTEASE INHIBITOR; ACTIVE-SITE; PROTONATION STATE; STRUCTURAL IMPLICATIONS; CRYSTAL-STRUCTURES; VIRAL INFECTIVITY; WATER-MOLECULES;
D O I
10.1016/j.molstruc.2012.03.057
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Acquired immune deficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV), which is infecting more humans and is expanding faster in the world. The illness interferes with the immune system, making people with AIDS much more likely to get infections, including opportunistic infections and tumors that do not affect people with working immune systems. HIV-1 PR is one of the major targets of anti-AIDS drug discovery. It is, therefore, necessary to develop some inhibitors against HIV-1 PR. In this work, we executed molecular dynamics (MDs) simulation of HIV-1 PR with drugs darunavir (DRV), amprenavir (APV), nelfinavir (NFV), and examined the resistant mechanism of L101, G48V, 154V, and L90M mutations of this PR, aiming at designing promising drugs. The comparative analysis suggests that the existences of dodecahydroisoquinoline ring at P1' subsite, 4-aminophenylsulfonamide at P2' subsite, and bis-tetrahydrofuranylurethane at P2 subsite are helpful for maintaining the high affinity of the inhibitor for the protease and exhibiting high potency against multiple drug resistance (MDR) mutant protease. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:227 / 235
页数:9
相关论文
共 50 条
  • [41] Structure-function studies of HIV-1 protease drug resistance to tipranavir and darunavir
    Kovari, L. C.
    Wang, Y.
    Brunzelle, J.
    ANTIVIRAL THERAPY, 2011, 16 : A61 - A61
  • [42] Drug-resistant genotyping in HIV-1 therapy
    Zöllner, B
    Feucht, HH
    Weitner, L
    Adam, A
    Laufs, R
    LANCET, 1999, 354 (9184): : 1120 - 1121
  • [43] Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains
    Qi, Qianqian
    Wang, Qian
    Chen, Weizao
    Yu, Fei
    Du, Lanying
    Dimitrov, Dimiter S.
    Lu, Lu
    Jiang, Shibo
    JOURNAL OF INFECTION, 2017, 75 (01) : 68 - 71
  • [44] Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection
    Metzner, Karin J.
    Scherrer, Alexandra U.
    Preiswerk, Benjamin
    Joos, Beda
    von Wyl, Viktor
    Leemann, Christine
    Rieder, Philip
    Braun, Dominique
    Grube, Christina
    Kuster, Herbert
    Boeni, Juerg
    Yerly, Sabine
    Klimkait, Thomas
    Aubert, Vincent
    Furrer, Hansjakob
    Battegay, Manuel
    Vernazza, Pietro L.
    Cavassini, Matthias
    Calmy, Alexandra
    Bernasconi, Enos
    Weber, Rainer
    Guenthard, Huldrych F.
    JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (07): : 1102 - 1112
  • [45] Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants
    Li, Min
    Passos, Dario Oliveira
    Shan, Zelin
    Smith, Steven J.
    Sun, Qinfang
    Biswas, Avik
    Choudhuri, Indrani
    Strutzenberg, Timothy S.
    Haldane, Allan
    Deng, Nanjie
    Li, Zhaoyang
    Zhao, Xue Zhi
    Briganti, Lorenzo
    Kvaratskhelia, Mamuka
    Burke Jr, Terrence R. R.
    Levy, Ronald M.
    Hughes, Stephen H.
    Craigie, Robert
    Lyumkis, Dmitry
    SCIENCE ADVANCES, 2023, 9 (29)
  • [46] Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity
    Prado, JG
    Wrin, T
    Beauchaine, J
    Ruiz, L
    Petropoulos, CJ
    Frost, SDW
    Clotet, B
    D'Aquila, RT
    Martinez-Picado, J
    AIDS, 2002, 16 (07) : 1009 - 1017
  • [47] HIV-1 Protease as DNA Immunogen against Drug Resistance in HIV-1 Infection: DNA Immunization with Drug Resistant HIV-1 Protease Protects Mice from Challenge with Protease-Expressing Cells
    Petkov, Stefan
    Kilpelaeinen, Athina
    Bayurova, Ekaterina
    Latanova, Anastasia
    Mezale, Dzeina
    Fridrihsone, Ilse
    Starodubova, Elizaveta
    Jansons, Juris
    Dudorova, Alesja
    Gordeychuk, Ilya
    Wahren, Britta
    Isaguliants, Maria
    CANCERS, 2023, 15 (01)
  • [48] Characterization of HIV-1 resistant isolates generated during in vitro passage with both atazanavir and amprenavir in combination
    Cabrera, C.
    Marfil, S.
    Garcia, E.
    Bofill, M.
    Clotet, B.
    Ruiz, L.
    ANTIVIRAL THERAPY, 2006, 11 (05) : S153 - S153
  • [49] HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants
    Smith, Steven J.
    Zhao, Xue Zhi
    Passos, Dario Oliveira
    Pye, Valerie E.
    Cherepanov, Peter
    Lyumkis, Dmitry
    Burke, Terrence R., Jr.
    Hughes, Stephen H.
    ACS INFECTIOUS DISEASES, 2021, 7 (06): : 1469 - 1482
  • [50] Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination
    Schader, Susan M.
    Colby-Germinario, Susan P.
    Schachter, Jordana R.
    Xu, Hongtao
    Wainberg, Mark A.
    AIDS, 2011, 25 (13) : 1585 - 1594